IMDX
Insight Molecular Diagnostics Inc.
3.60$
+6.2%
vs. previous close
Closing price · As of: Sep 30, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -23.3% | +100.3% | +13.5% | -29.3% | -6.8% | +318.8% | +39.0% | +187.9% | -37.3% | -25.2% | -53.2% | -26.6% | |
| – | -24.7% | +199.2% | +16.2% | -32.8% | +1.3% | +165.6% | -59.8% | +324.3% | -34.8% | -58.1% | +9.9% | +30.2% | |
| – | +154.5% | +3,011.3% | +27.2% | -25.3% | +5.7% | +174.7% | -67.6% | +361.3% | -39.3% | -52.8% | -8.4% | +34.1% | |
| – | -25.2% | +197.9% | +17.8% | -32.6% | +1.2% | +165.3% | -65.2% | +333.0% | -39.7% | -53.8% | -8.4% | +34.1% | |
| – | – | – | – | – | – | – | – | +607.9% | +40.0% | -75.9% | +233.3% | -30.1% | |
| – | – | – | – | – | – | – | – | – | +597.7% | -100.0% | – | +8.8% | |
| – | – | – | – | – | – | – | – | +103.4% | -100.0% | – | – | – | |
| – | -14.1% | -16.4% | -19.7% | -24.5% | – | – | – | +311.2% | -0.1% | -8.2% | -74.2% | – | |
| – | +59.0% | -68.9% | +98.1% | +26.8% | +4.9% | +48.0% | +143.2% | +330.1% | -35.9% | -10.0% | -13.0% | +20.8% | |
| – | +59.0% | -68.9% | +84.7% | +4.2% | +24.9% | -20.2% | +102.6% | +57.0% | -14.3% | -40.6% | +1.1% | +66.0% | |
| – | +98.8% | – | – | +630.7% | +6.4% | +1.0% | +77.4% | -24.2% | -61.8% | -18.4% | +94.7% | +39.5% | |
| – | +39.8% | +97.9% | +48.1% | -58.5% | -5.1% | +182.5% | -7.9% | +319.0% | -30.8% | -23.9% | +139.1% | +11.6% | |
| – | -129.7% | – | -5.3% | -55.4% | -22.3% | +800.9% | +8.6% | +94.8% | -39.3% | -48.3% | -160.0% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +235.7% | -3.6% | +26.3% | +13.8% | +25.4% | +35.5% | +27.6% | +35.8% | +24.6% | +38.1% | +70.8% | +133.2% |
Data as of: September 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.